T S Bhat1, C M Herbosa1, A R Rosenberg1, O Sogade1, D B Jeffe2, N Mehta-Shah3, Y R Semenov4,5, A C Musiek1. 1. Division of Dermatology, Washington University School of Medicine, St Louis, MO, USA. 2. Department of Medicine, Washington Unive, St Louis, MO, USA. 3. Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA. 4. Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA. 5. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) negatively impacts quality of life (QoL), but existing QoL questionnaires may not comprehensively reflect patients' experience. OBJECTIVES: To identify the aspects of QoL that are most meaningful to patients with CTCL and to evaluate existing QoL instruments in this context. METHODS: Semistructured interviews were conducted between May and June 2019 using purposive sampling of patients with CTCL. Data were analysed by an inductive thematic approach using Dedoose Version 8.0.35. RESULTS: One-on-one interviews lasting a median of 43 min were completed by 18 patients [median age 62 years (interquartile range 52-70); 39% advanced-stage (IIB-IV)]. Itch was the most common clinical symptom reported (16 of 18 patients), followed by pain (12 of 18), skin breaks (11 of 18) and skin flaking (10 of 18). Eleven patients reported that their symptoms interfered with sleep, which impacted daily functioning. Patients also noted a lack of understanding of the disease in the community and felt uncertain (12 of 18), depressed (11 of 18), suicidal (four of 18) and hopeless (nine of 18). Nearly all patients (17 of 18) reported a sense of 'otherness' (not feeling 'normal' or 'like themselves'), and most patients (16 of 18) specifically mentioned concern about their physical appearance. Patients also noted substantial treatment burden. Salient patient concerns, including individual clinical symptoms, concern about appearance and problems with sleep, were not adequately or consistently represented in generic, skin-specific or CTCL-specific QoL measures. CONCLUSIONS: Incorporating the concerns and priorities that distinguish patients with CTCL from other patient populations will be of paramount importance in developing a comprehensive CTCL-specific measure of QoL that adequately captures patients' experience.
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) negatively impacts quality of life (QoL), but existing QoL questionnaires may not comprehensively reflect patients' experience. OBJECTIVES: To identify the aspects of QoL that are most meaningful to patients with CTCL and to evaluate existing QoL instruments in this context. METHODS: Semistructured interviews were conducted between May and June 2019 using purposive sampling of patients with CTCL. Data were analysed by an inductive thematic approach using Dedoose Version 8.0.35. RESULTS: One-on-one interviews lasting a median of 43 min were completed by 18 patients [median age 62 years (interquartile range 52-70); 39% advanced-stage (IIB-IV)]. Itch was the most common clinical symptom reported (16 of 18 patients), followed by pain (12 of 18), skin breaks (11 of 18) and skin flaking (10 of 18). Eleven patients reported that their symptoms interfered with sleep, which impacted daily functioning. Patients also noted a lack of understanding of the disease in the community and felt uncertain (12 of 18), depressed (11 of 18), suicidal (four of 18) and hopeless (nine of 18). Nearly all patients (17 of 18) reported a sense of 'otherness' (not feeling 'normal' or 'like themselves'), and most patients (16 of 18) specifically mentioned concern about their physical appearance. Patients also noted substantial treatment burden. Salient patient concerns, including individual clinical symptoms, concern about appearance and problems with sleep, were not adequately or consistently represented in generic, skin-specific or CTCL-specific QoL measures. CONCLUSIONS: Incorporating the concerns and priorities that distinguish patients with CTCL from other patient populations will be of paramount importance in developing a comprehensive CTCL-specific measure of QoL that adequately captures patients' experience.
Authors: T Beynon; L Selman; E Radcliffe; S Whittaker; F Child; D Orlowska; C Morgans; S Morris; R Harding Journal: Br J Dermatol Date: 2015-05-28 Impact factor: 9.302
Authors: J R Chalmers; K S Thomas; C Apfelbacher; H C Williams; C A Prinsen; P I Spuls; E Simpson; L A A Gerbens; M Boers; S Barbarot; J F Stalder; K Abuabara; V Aoki; M Ardeleanu; J Armstrong; B Bang; T L Berents; T Burton; L Butler; T Chubachi; A Cresswell-Melville; A DeLozier; L Eckert; L Eichenfield; C Flohr; M Futamura; A Gadkari; E S Gjerde; K F van Halewijn; C Hawkes; L Howells; L Howie; R Humphreys; H A Ishii; Y Kataoka; I Katayama; W Kouwenhoven; S M Langan; Y A Leshem; S Merhand; P Mina-Osorio; H Murota; T Nakahara; F P Nunes; U Nygaard; M Nygårdas; Y Ohya; E Ono; E Rehbinder; N K Rogers; G L E Romeijn; M L A Schuttelaar; A V Sears; M A Simpson; J A Singh; J Srour; B Stuart; Å Svensson; G Talmo; H Talmo; H D Teixeira; J P Thyssen; G Todd; F Torchet; A Volke; L von Kobyletzki; E Weisshaar; A Wollenberg; M Zaniboni Journal: Br J Dermatol Date: 2018-04-19 Impact factor: 9.302
Authors: F Sampogna; M Frontani; G Baliva; G A Lombardo; G Alvetreti; C Di Pietro; S Tabolli; G Russo; D Abeni Journal: Br J Dermatol Date: 2008-12-16 Impact factor: 9.302
Authors: Jennifer A Salant; Niloufer Khan; Judith E Nelson; Moe Norton-Westbrook; Anjali V Desai Journal: J Palliat Med Date: 2021-12-31 Impact factor: 2.947
Authors: Edgar Dippel; Chalid Assaf; Jürgen C Becker; Michael von Bergwelt-Baildon; Sophie Bernreiter; Antonio Cozzio; Hans T Eich; Khaled Elsayad; Markus Follmann; Stephan Grabbe; Uwe Hillen; Wolfram Klapper; Claus-Detlev Klemke; Carmen Loquai; Frank Meiss; Christina Mitteldorf; Ulrike Wehkamp; Dorothee Nashan; Jan P Nicolay; Ilske Oschlies; Max Schlaak; René Stranzenbach; Rose Moritz; Christoph Stoll; Tibor Vag; Michael Weichenthal; Marion Wobser; Rudolf Stadler Journal: J Dtsch Dermatol Ges Date: 2022-04 Impact factor: 5.231
Authors: Mille Vissing; John Ploen; Mascha Pervan; Kitt Vestergaard; Mazen Schnefeldt; Stine Krog Frandsen; Søren Rafael Rafaelsen; Christina Louise Lindhardt; Lars Henrik Jensen; Achim Rody; Julie Gehl Journal: BMJ Open Date: 2021-06-16 Impact factor: 2.692
Authors: R Ottevanger; S van Beugen; A W M Evers; R Willemze; M H Vermeer; K D Quint Journal: J Eur Acad Dermatol Venereol Date: 2021-08-14 Impact factor: 9.228